DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
PRECISION BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.19+0.42 (+7.28%)
Close on Oct 19, 2026
- Market cap
- $160.05M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.71 (−10.29%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
PRECISION BIOSCIENCES INC grew revenue 3473.0% to $45.06M over the twelve months to Jun 30, 2026. Free cash flow was -$51.94M.
Revenue
$45.06M
+3473.0% vs. a year earlier
Operating income
-$36.40M
TTM Q2 2026
Free cash flow
-$51.94M
TTM Q2 2026
EPS, diluted
-$3.56
-442.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $160.05M
- P/E ratio
- –
- Price to sales
- 3.55
- Price to book
- 3.53
- Dividend yield
- –
- Free cash flow yield
- -32.45%
Fundamentals
- Revenue
- $45.06M
- Net income
- -$52.73M
- EPS, diluted
- -$3.56
- Free cash flow
- -$51.94M
- Book value per share
- $1.75
- Diluted shares
- 26M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$45.06M+3473.0% YoY
Operating income
-$36.40M
Net income
-$52.73M
EPS, diluted
–
Free cash flow
-$51.94M
Reported periodTrailing twelve months